Cardio renal metabolic (CRM)

Menopause in Primary care: HRT safety, LDL lipids and new NICE guidance

Apr 8, 2026

•

8 min read

Menopause in Primary care: HRT safety, LDL lipids and new NICE guidance

From raised LDL to a new non-hormonal drug class and the largest HRT safety study to date, this week is all menopause in primary care.

Cardio renal metabolic (CRM)

FALLING THROUGH THE GAAP: WHEN PATIENTS DIAGNOSE THEMSELVES

Apr 2, 2026

•

3 min read

FALLING THROUGH THE GAAP: WHEN PATIENTS DIAGNOSE THEMSELVES

One in 10 patients surveyed by Kidney Care UK found out they had CKD by seeing it recorded in the NHS App. Almost 40% had no opportunity to discuss the diagnosis with a healthcare professional.

Cardio renal metabolic (CRM)

EMPA-KIDNEY: Could the benefits outlast the drug?

Apr 2, 2026

•

4 min read

EMPA-KIDNEY: Could the benefits outlast the drug?

When a patient stops a medication, the assumption is usually that the benefits stop too. For most drugs, that is exactly what happens. The EMPA-KIDNEY post-trial follow-up, published in NEJM, checked if this idea is true for SGLT2 inhibitors in CKD.

Cardio renal metabolic (CRM)

THE KIDNEY FAILURE RISK EQUATION: WHO SHOULD WE REFER?

Apr 2, 2026

•

4 min read

THE KIDNEY FAILURE RISK EQUATION: WHO SHOULD WE REFER?

The kidney failure risk equation is now in NICE guidance. A new BJGP study from Greater Manchester found that, for most patients, the risk of death is much higher than the risk of needing dialysis.

Cardio renal metabolic (CRM)

COBRRA DELIVERS THE FIRST HEAD-TO-HEAD DOAC COMPARISON IN VTE

Mar 27, 2026

•

3 min read

COBRRA DELIVERS THE FIRST HEAD-TO-HEAD DOAC COMPARISON IN VTE

For over a decade, the question of whether to use apixaban or rivaroxaban for treating acute venous thromboembolism (VTE) has remained. Both are considered efficacious.COBRA Trial | N Engl J Med

Cardio renal metabolic (CRM)

What could the antihypertensive medication landscape look like in the future?

Mar 19, 2026

•

5 min read

What could the antihypertensive medication landscape look like in the future?

Low-dose multi-drug pills are key and new ways to tackle resistant hypertension are emerging. Since 2022, many Phase III antihypertensive trials have been reported. We looked at these studies to sketch a future that may move away from the usual monotherapy-first method.

Cardio renal metabolic (CRM)

Statins past 80: what does the evidence actually say?

Mar 19, 2026

•

3 min read

Statins past 80: what does the evidence actually say?

At what age do you stop offering statins for primary prevention? It's a question the guidelines can only partially answer.

Cardio renal metabolic (CRM)

Treating older patients in primary care: the decisions guidelines don’t cover

Mar 18, 2026

•

11 min read

Treating older patients in primary care: the decisions guidelines don’t cover

From statin use past 80 to new hypertension therapies and AI in care homes, a practical update for UK primary care clinicians.

Cardio renal metabolic (CRM)

The first first large-scale comparative data: SGLT-2i vs. GLP-1 RA for kidney outcomes

Mar 11, 2026

•

12 min read

The first first large-scale comparative data: SGLT-2i vs. GLP-1 RA for kidney outcomes

PLUS: a year of NICE guideline changes, HRT evidence reviewed, and rare disease in UK primary care.

Cardio renal metabolic (CRM)

The Flozin-First Era, and 810,000 More GLP-1 Patients

Feb 22, 2026

•

5 min read

The Flozin-First Era, and 810,000 More GLP-1 Patients

NICE Rewrites the Type 2 Diabetes Script

Cardio renal metabolic (CRM)

Art The art of "Diagnostic Elegance": Refocusing the hypertension review

Feb 5, 2026

•

3 min read

Art The art of "Diagnostic Elegance": Refocusing the hypertension review

Recent evidence suggests that we are 'over-testing' our hypertension patients, says report from BJGP